Navan Technologies Inc., of South San Francisco, said it closed a seed investment round led by Amgen Ventures, High-Tech Gründerfonds, Hemi Ventures and other institutional and private investors. Navan is developing cell and gene therapies using its nonviral Nanostraw platform based on technology licensed from Stanford University.